This article was originally published in The Tan Sheet
The company says it is not in any early stage evaluation of Nasocort as an Rx-to OTC switch candidate. "The Tan Sheet" reported in "Health News Daily" Wed. May 5 that Aventis was looking as Nasocort as a prospect...
You may also be interested in...
The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.
The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.